Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited, and prognosis is poor. Nivolumab (Opdivo) has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastati...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwab, Katjana S., Kristiansen, Glenn, Schild, Hans H., Held, Stefanie E.A., Heine, Annkristin, Brossart, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836192/
https://www.ncbi.nlm.nih.gov/pubmed/29515404
http://dx.doi.org/10.1159/000485562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836192/
https://www.ncbi.nlm.nih.gov/pubmed/29515404
http://dx.doi.org/10.1159/000485562

Ejemplares similares